Dr Hamid on the Investigation of Fianlimab With Cemiplimab in Advanced Melanoma
June 13th 2023Omid Hamid, MD, discusses the investigation of the LAG-3 inhibitor fianlimab in combination with cemiplimab in patients with advanced melanoma who were naïve to anti–PD-1 agents in the advanced setting.
Read More
Dr. Hamid on Melanoma as a Therapeutic Driver for Other Cancers
February 12th 2017Omid A. Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses melanoma as a therapeutic driver for other tumor types during the 13th Annual 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® in Sunny Isles Beach, Florida.
Read More
Dr. Hamid on Patient Selection for Immunotherapy Regimens in Melanoma
December 30th 2016Omid A. Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses how to accurately select patients who are likely to have durable and long responses with single-agent immunotherapy versus combination treatment.
Read More